Banco Bilbao Vizcaya Argentaria S.A. Purchases 3,768 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its stake in Thermo Fisher Scientific Inc. by 16.5% in Q1, owning 26,624 shares valued at $13,255,000.
• The company recently reported $5.36 earnings per share for the last quarter, exceeding estimates and showing a 2.9% year-over-year revenue increase.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, with an ex-dividend date set for September 15th.

Banco Bilbao Vizcaya Argentaria S.A. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,624 shares of the medical research company's stock after acquiring an additional 3,768 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Thermo Fisher Scientific were worth $13,255,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after acquiring an additional 230,382 shares during the period. Northern Trust Corp lifted its position in Thermo Fisher Scientific by 13.2% during the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock valued at $2,034,107,000 after acquiring an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. lifted its position in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Thermo Fisher Scientific by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock valued at $1,455,774,000 after acquiring an additional 115,463 shares during the period. Finally, Pictet Asset Management Holding SA lifted its position in Thermo Fisher Scientific by 7.2% during the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock valued at $1,432,816,000 after acquiring an additional 193,378 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of several recent analyst reports. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Finally, Wells Fargo & Company decreased their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 295 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,591,606.96. This represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,896 shares of company stock valued at $8,593,838 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $16.4780 during trading hours on Friday, hitting $500.2380. 1,778,365 shares of the company's stock traded hands, compared to its average volume of 2,406,376. The business's fifty day moving average price is $443.02 and its two-hundred day moving average price is $457.46. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $188.89 billion, a P/E ratio of 28.93, a P/E/G ratio of 2.58 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.